Corcept Therapeutics (CORT) Tops Q2 EPS by 10c; Reaffirms
Tweet
Share
E-mailGet Alerts CORT Hot Sheet
Price: $113.39 +0.01%
Revenue Growth %: +54.6%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
RCBC, GASS, YSG, More
Revenue Growth %: +54.6%
Financial Fact:
Basic and diluted net loss per share: 0.02
Today's EPS Names:
RCBC, GASS, YSG, More
Join SI Premium – FREE
Corcept Therapeutics (NASDAQ: CORT) reported Q2 EPS of $0.32, $0.10 better than the analyst estimate of $0.22. Revenue for the quarter came in at $88.6 million versus the consensus estimate of $90.14 million.
GUIDANCE:
Corcept Therapeutics reaffirms FY2020 revenue of $355-375 million.
For earnings history and earnings-related data on Corcept Therapeutics (CORT) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sprinklr (CXM) Tops Q2 EPS by 1c, Offers Guidance
- MongoDB (MDB) Tops Q2 EPS by 29c, Beats on Revenue; Offers FY37 Guidance
- Credo Technology Group Holding (CRDO) Tops Q1 EPS by 4c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
